Search Results for: DRUG DEVELOPMENT To DeRisk Patient
Articles
SPECIAL FEATURE - PFS & Parenteral Drug Delivery: Self-Injection is Very Much the “New Normal” May 2, 2022
Contributor Cindy H. Dubin showcases how leading CDMOs and drug delivery developers are responding to current market trends to create ergonomic technologies that are patient friendly, easy to use, reduce needle anxiety, and feature improved packaging materials.
SPECIAL FEATURE - Platform Technologies - Derisking & Transforming Drug Development September 29, 2017
Contributor Cindy H. Dubin, in this second annual report, speaks with several exciting and innovative companies whose platform technologies are transforming drug development.
Aptar Expands Pharmaceutical Services; Announces Exclusive Collaboration Between Aptar Pharma & Fluidda September 22, 2022
Nanopharm, an Aptar Pharma company and leader in contract research and development services for orally inhaled and nasal drug products, recently announced an exclusive collaboration with Fluidda, a leader in the field of Functional Respiratory Imaging…..
Aptar Pharma’s Nasal Unidose Device Approved by US FDA January 24, 2020
Aptar Pharma recently announced that its patented Unidose Liquid System is the device delivering a new nasal spray approved by the US FDA as a rescue treatment for….
